Ocular Therapeutix, Inc.

Deepak Sambhara MD, FASRS, Courtney Crawford MD FACS, and Samuel Minaker, MD, MS shared perspectives at Retina World Congress on the future of wet age-related macular degeneration (AMD) care. The discussion explored the importance of clinical trial design that evaluates durability, meaningful endpoints, and the potential to improve long-term outcomes for patients. As the retina landscape continues to evolve, we aim to redefine wet AMD treatment to support physicians, patients, and care partners. Explore more: https://bit.ly/4tM8KdZ #RetinaOnRecord #RetinaWorldCongress #RetinaRedefined

Our Executive Chairman, President, and CEO Pravin Dugel, MD will join Stifel Bank's Ophthalmology Conference to discuss the future of retinal disease treatment and share insights from our landmark SOL-1 Phase 3 superiority clinical trial in wet age-related macular degeneration. As our clinical programs continue to advance, we remain focused on the potential to redefine the retina experience with the goal of delivering greater durability, reducing treatment burden, and improving long-term outcomes for patients. Learn more: https://ow.ly/C2Me50Z1Hnq #RetinaRedefined

At The Royal College of Ophthalmologists (RCOphth) Congress, Adnan Tufail, MBBS, MD, Darius M. Moshfeghi MD, and Dilsher Dhoot, MD spotlighted new analyses related to our landmark SOL-1 Phase 3 clinical trial. This global forum was an important opportunity to share our focus and progress as we aim to deliver durable treatment approaches and improve long-term outcomes for patients. Learn more: www.ocutx.com #RetinaRedefined

Investor Day is almost here! We’re excited to join the investor community on June 17 at 2:00 PM ET in New York City. Leading retinal disease key opinion leaders and members of our senior leadership team will share updates on our strategy, momentum across our clinical progress, and commitment to advancing the future of retinal care. Learn more: https://ow.ly/yt5U50Z1OY2 #RetinaRedefined

We're thrilled to introduce our newest team members! Their expertise and enthusiasm will be invaluable. Welcome aboard! #OcularExperience #NewHires

At Retina World Congress, our team was proud to share data from our landmark SOL-1 Phase 3 superiority clinical trial in wet age-related macular degeneration (AMD) with the global retina community, highlighting the importance of durability and sustained disease control in wet AMD management. These conversations continue to inspire innovation and drive progress as we aim to redefine the retina experience. Learn more: https://ow.ly/hUw450Z1H6p #RetinaWorldCongress #RetinaRedefined

Patricio Schlottmann, MD presented on the landmark SOL‑1 Phase 3 clinical trial in wet age-related macular degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO). He highlighted how innovative clinical trial design may help inform the future of durability and sustained disease control in retinal care. These insights reflect our commitment to advancing treatment options that aim to better meet patient needs and help redefine their outcomes. Learn more: https://ow.ly/zXkF50Z08He #ARVO2026 #RetinaRedefined #RetinaOnRecord 𝘛𝘩𝘪𝘴 𝘤𝘰𝘯𝘵𝘦𝘯𝘵 𝘥𝘪𝘴𝘤𝘶𝘴𝘴𝘦𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘳𝘶𝘨, 𝘖𝘛𝘟-𝘛𝘒𝘐 (𝘢𝘭𝘴𝘰 𝘳𝘦𝘧𝘦𝘳𝘳𝘦𝘥 𝘵𝘰 𝘢𝘴 𝘈𝘟𝘗𝘈𝘟𝘓𝘐™), 𝘪𝘯 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵. 𝘖𝘛𝘟-𝘛𝘒𝘐’𝘴 𝘦𝘧𝘧𝘪𝘤𝘢𝘤𝘺 𝘢𝘯𝘥 𝘴𝘢𝘧𝘦𝘵𝘺 𝘱𝘳𝘰𝘧𝘪𝘭𝘦𝘴 𝘩𝘢𝘷𝘦 𝘯𝘰𝘵 𝘣𝘦𝘦𝘯 𝘦𝘴𝘵𝘢𝘣𝘭𝘪𝘴𝘩𝘦𝘥, 𝘢𝘯𝘥 𝘪𝘵 𝘩𝘢𝘴 𝘯𝘰𝘵 𝘣𝘦𝘦𝘯 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘮𝘢𝘳𝘬𝘦𝘵𝘪𝘯𝘨 𝘣𝘺 𝘵𝘩𝘦 𝘜.𝘚. 𝘍𝘰𝘰𝘥 𝘢𝘯𝘥 𝘋𝘳𝘶𝘨 𝘈𝘥𝘮𝘪𝘯𝘪𝘴𝘵𝘳𝘢𝘵𝘪𝘰𝘯 (𝘍𝘋𝘈) 𝘰𝘳 𝘢𝘯𝘺 𝘰𝘵𝘩𝘦𝘳 𝘩𝘦𝘢𝘭𝘵𝘩 𝘢𝘨𝘦𝘯𝘤𝘺.

We’re looking forward to our first international presentation at the The Royal College of Ophthalmologists (RCOphth) Congress, where Adnan Tufail, MD, Darius M. Moshfeghi, MD, and Ocular’s Chief Scientific Officer Jeffrey Heier, MD, will discuss the results of our landmark SOL-1 Phase 3 trial. As Ocular’s clinical trials in wet age-related macular degeneration advance, we remain focused on durable treatment and improving long-term outcomes for patients. Explore how we’re working to advance retinal disease treatment: www.ocutx.com #RetinaRedefined

Meet G. Dawson Depperschmidt, Senior Associate in Business Operations, whose passion to make an impact for patients drives her to advance Ocular's mission. “Vision is such a fundamental part of how we experience the world,” Dawson shares. “Being part of an organization advancing treatments for retinal disease is incredibly meaningful to me.” Thank you, Dawson, for your commitment to redefining the retina experience. Learn more about life at Ocular: www.ocutx.com/careers/ #OcularOutlook #RetinaRedefined

Andrew Moshfeghi, MD shared findings from a real‑world analysis of anti‑VEGF treatment utilization and vision outcomes in wet age‑related macular degeneration (AMD) from the Vestrum Database at Association for Research in Vision and Ophthalmology (ARVO). These real-world insights highlight how treatment burden and adherence may contribute to suboptimal long-term visual outcomes, reinforcing the need for more durable approaches to wet AMD management. Learn more: https://bit.ly/4wo16ZK #ARVO2026 #RetinaRedefined #RetinaOnRecord